Clopidogrel resistance: The way forward
Indian Heart Journal, 2014 Clopidogrel, a second generation thienopyridine has been the mainstay of ACS (Acute Coronary Syndrome) treatment for more than a decade. Clopidogrel Resistance has been associated with increased mortality in ACS patients with an increase in number of ...
Shuvanan Ray
doaj +1 more source
Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry. [PDF]
PLoS ONE, 2013 BACKGROUND: The efficacy of clopidogrel is inconclusive in the chronic kidney disease (CKD) population with acute coronary syndrome (ACS). Furthermore, CKD patients are prone to bleeding with antiplatelet therapy.
Tsung-Hsien Lin +9 more
doaj +1 more source
Stroke genetics: prospects for personalized medicine. [PDF]
, 2012 Epidemiologic evidence supports a genetic predisposition to stroke. Recent advances, primarily using the genome-wide association study approach, are transforming what we know about the genetics of multifactorial stroke, and are identifying novel stroke ...
A Gschwendtner +55 more
core +2 more sources
Cytochrome p-450 polymorphisms and response to clopidogrel.
New England Journal of Medicine, 2009 BACKGROUND Clopidogrel requires transformation into an active metabolite by cytochrome P-450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are polymorphic, with common alleles conferring reduced function.
J. Mega +10 more
semanticscholar +1 more source
Scientific Reports, 2021 Clopidogrel is converted to its active metabolite by cytochrome P450 isoenzymes and irreversibly inhibits platelet activation by antagonizing the adenosine-diphosphate (ADP) receptor.
Yu Ueda +8 more
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2015 Aim. To study prevalence of resistance to acetylsalicylic acid, clopidogrel and dual resistance in percutaneous coronary intervention (PCI), to identify clinical risk factors of resistance development, to study effects of concomitant therapy on ...
V. A. Sulimov, E. V. Moroz
doaj +3 more sources
Cessation of dual antiplatelet therapy and cardiovascular events following acute coronary syndrome [PDF]
, 2019 Objective: To assess whether cardiovascular events are increased after cessation of dual antiplatelet therapy (DAPT) following acute coronary syndrome (ACS) and to explore predictors for recurrent events after DAPT cessation during long-term follow-up.
Berry, Colin +3 more
core +1 more source
, 2010 Publisher Summary Clopidogrel contains a center of dissymmetry, and hence is capable of being resolved into its two mirror image compounds. It has been found that only the (S)-enantiomer, which corresponds to the dextrorotatory form, has antithrombotic activity and that the (R)-enantiomer, which corresponds to the levorotatory form, does not exhibit ...
Maria L.A.D. Lestari +3 more
openaire +3 more sources
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
New England Journal of Medicine, 2006 BACKGROUND Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events.
Deepak L. Bhatt +25 more
semanticscholar +1 more source
Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome [PDF]
, 2019 © The Author(s) 2019. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the ...
Gorog, Diana A +5 more
core +2 more sources